secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0001193125-21-352750
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q3 net loss narrows to $13.1M; completed $334.5M IPO
------------------------------------------------------------

- Net loss of $13.1M ($0.63 per share) narrowed from $120.2M ($11.71) in Q3 2020.
- R&D expenses fell to $4.7M from $116.9M; G&A increased to $8.9M from $2.1M.
- Completed IPO raising $334.5M gross ($311.1M net); cash position sufficient through 2023.
- Initiated PK study of mavacamten and Phase 2a trial of infigratinib in China.
- Appointed Jesse Wu and Susan Silbermann to board; new chief scientific advisor and China GM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000119312521352750/0001193125-21-352750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000119312521352750/d455505d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-352750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer